Jyothilakshmi Sajimon

Ms. Jyothilakshmi Sajimon

Cancer Biology, Centre For Human Genetics, Bengaluru, India
orcid
Project Assistant, Centre For Human Genetics, Bengaluru

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
NBNeeha Sinai Borker
Neeha Sinai Borker
Jyothilakshmi SajimonJyothilakshmi Sajimon
Jyothilakshmi Sajimon
SSSeemadri Subhadarshini
Seemadri Subhadarshini
RARifat Aara
Rifat Aara
MJMohit Kumar Jolly
Mohit Kumar Jolly
RNRadhika Nair
Radhika Nair
Metastatic cancer is the final frontier in disease progression with few avenues of treatment open to patients. The failure of therapeutic options at the end-stage disease is confounded by the presence of diverse clones in the metastatic tumor which contributes to intratumoral heterogeneity (ITH), resulting in intrinsic and acquired drug resistance. We aim to elucidate the contribution of ITH to the development of metastasis with a focus on the origins and molecular mechanisms driving ITH, as well as the clinical and technical challenges of acquiring and studying metastatic cohorts in which we can investigate this phenomenon. Bioinformatic approaches that could help in silico analysis will be discussed, which could shed light on how to design new therapeutic strategies for metastatic cancer and give hope to patients living under the shadow of the sword of Damocles.

28 February 2025 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
KSKavitha Sethumadhavan
Kavitha Sethumadhavan
Jyothilakshmi SajimonJyothilakshmi Sajimon
Jyothilakshmi Sajimon
PMPratyajit Mohapatra
Pratyajit Mohapatra
VRVictor Stalin Raj
Victor Stalin Raj

21 September 2024 in ACS Applied Bio Materials
Verified
Journal Article
Closed access
MLMahesh M. Lalitha
Mahesh M. Lalitha
SBSourav Banerjee
Sourav Banerjee
AJArya Jayaraj
Arya Jayaraj
AKAdithi Kamath
Adithi Kamath
DDDeepika Divakaran
Deepika Divakaran
Rajendra KurapatiRajendra Kurapati
Rajendra Kurapati

16 October 2025 in bioRxiv
Verified
Preprint
Open access
KSKavitha Modenkattil Sethumadhavan
Kavitha Modenkattil Sethumadhavan
GKGayatri Kandpal
Gayatri Kandpal
Jyothilakshmi SajimonJyothilakshmi Sajimon
Jyothilakshmi Sajimon
VDV. R. Akshay Das
V. R. Akshay Das
NBNirmegh Basu
Nirmegh Basu
DRDr. V. Stalin Raj
Dr. V. Stalin Raj
Gene cloning, site-directed mutagenesis (SDM), and short gene synthesis are essential tools in molecular biology, yet existing approaches remain constrained by efficiency, flexibility, and cost. Here, we developed a versatile, simple, and rapid (VSR) 3-in-1 method that integrates seamless cloning, mutagenesis, and short gene assembly in a single platform. This approach works on the principles of overlap extension polymerase chain reaction (O PCR ), uses high-fidelity DNA polymerase and short overlapping primers. Target genes can be directly amplified from genomic DNA or complementary DNA (cDNA) templates and cloned into vectors without intermediate purification, restriction enzyme digestion, or ligation. VSR supports the insertion of DNA fragments ranging from 80 bp to 33 kb at any plasmid locus while enabling the introduction of single or multiple nucleotide substitutions at one or more sites in a single reaction. Using this method, we cloned 35 genes of diverse lengths and two complete viral genomes with efficiencies ranging from 60–100% and introduced up to 17 substitutions in a single mutagenesis reaction. We further demonstrate efficient de novo synthesis of short genes from overlapping oligonucleotides. The VSR method is a reliable, rapid, and cost-effective approach with a wide range of applications for both routine and high-throughput workflows. GRAPHICAL

27 April 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
NBNeeha Sinai Borker
Neeha Sinai Borker
Jyothilakshmi SajimonJyothilakshmi Sajimon
Jyothilakshmi Sajimon
SSSeemadri Subhadarshini
Seemadri Subhadarshini
RARifat Aara
Rifat Aara
MJMohit Kumar Jolly
Mohit Kumar Jolly
RNRadhika Nair
Radhika Nair
Metastatic cancer is the final frontier in disease progression with few avenues of treatment open to patients. The failure of therapeutic options at the end-stage disease is confounded by the presence of diverse clones in the metastatic tumor which contributes to intratumoral heterogeneity (ITH) resulting in intrinsic and acquired drug resistance. We aim to elucidate the contribution of ITH to the development of metastasis with a focus on the origins and molecular mechanisms driving ITH, as well as the clinical and technical challenges of acquiring and studying metastatic cohorts in which we can investigate this phenomenon. Bioinformatic approaches that could help in silico analysis will be discussed which could shed light on how to design new therapeutic strategies for metastatic cancer and give hope to patients living under the shadow of the sword of Damocles.

28 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
RARifat Aara
Rifat Aara
NBNeeha Sinai Borker
Neeha Sinai Borker
Jyothilakshmi SajimonJyothilakshmi Sajimon
Jyothilakshmi Sajimon
SSSeemadri Subhadarshini
Seemadri Subhadarshini
VSVp Snijesh
Vp Snijesh
RNRadhika Nair
Radhika Nair
Metastatic breast cancer (mBC) remains an incurable disease with limited treatment options, highlighting the need for novel therapeutic approaches. Combination therapy with chemotherapeutic agents along with targeted therapy are the most common methods of treatment used in the terminal stages of the disease. Eventual development of resistance to these approaches, leading to fatal outcomes suggests the presence or emergence of a heterogenous population of cells intrinsically resistant to commonly used regimens. Previous work identified a heterogeneous population of metastatic tumor cells with distinct molecular characteristics driven by Macc1 (Metastasis Associated in Colon Cancer 1) overexpression, which could be targeted by lovastatin (transcriptional inhibitor of Macc1). Building on this foundation, the efficacy of lovastatin in targeting metastatic cells with high Macc1 expression was evaluated in lung metastasis, and the regulatory pathways governing Macc1 expression and lovastatin treatment in mBC were investigated. The expression of Macc1, in breast cancer biopsies provides insights into the intra and inter tumor heterogeneity of the Macc1 gene and its correlation with disease outcomes. While some studies suggest synergistic effects between statins and chemotherapeutic agents, comprehensive evaluations of various combinations and their therapeutic outcomes are still needed. The therapeutic efficacy of lovastatin combined with chemotherapy to determine the most effective treatment regimen that maximizes tumor cell ablation demonstrated that lovastatin can effectively ablate the chemoresistant tumor cells in mBC. The translational implications of this research will identify patient subgroups that may benefit most from statin-chemotherapy combinations that could support the repurposing of statins as cost-effective adjuvant therapies for mBC.